IL252036B - Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof - Google Patents
Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereofInfo
- Publication number
- IL252036B IL252036B IL252036A IL25203617A IL252036B IL 252036 B IL252036 B IL 252036B IL 252036 A IL252036 A IL 252036A IL 25203617 A IL25203617 A IL 25203617A IL 252036 B IL252036 B IL 252036B
- Authority
- IL
- Israel
- Prior art keywords
- pyrimidine
- preparation
- method therefor
- pyridine compounds
- pharmaceutical uses
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410619334 | 2014-11-05 | ||
| CN201510152615.0A CN105085489B (zh) | 2014-11-05 | 2015-04-01 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| PCT/CN2015/093815 WO2016070816A1 (zh) | 2014-11-05 | 2015-11-05 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL252036A0 IL252036A0 (en) | 2017-06-29 |
| IL252036B true IL252036B (en) | 2021-09-30 |
Family
ID=54566905
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL252036A IL252036B (en) | 2014-11-05 | 2017-04-30 | Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof |
| IL286165A IL286165B2 (en) | 2014-11-05 | 2021-09-05 | Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL286165A IL286165B2 (en) | 2014-11-05 | 2021-09-05 | Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US10179784B2 (enExample) |
| EP (2) | EP3885344B1 (enExample) |
| JP (1) | JP6637058B2 (enExample) |
| KR (1) | KR102560052B1 (enExample) |
| CN (5) | CN111170998B (enExample) |
| CA (1) | CA2966376C (enExample) |
| ES (1) | ES2881622T3 (enExample) |
| IL (2) | IL252036B (enExample) |
| WO (1) | WO2016070816A1 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111875585B (zh) * | 2014-06-12 | 2023-06-23 | 上海艾力斯医药科技股份有限公司 | 一类激酶抑制剂 |
| CN106458969A (zh) * | 2014-08-25 | 2017-02-22 | 四川海思科制药有限公司 | 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途 |
| ES2886887T3 (es) * | 2014-10-11 | 2021-12-21 | Shanghai Hansoh Biomedical Co Ltd | Inhibidor de EGFR y preparación y aplicación del mismo |
| CN111170998B (zh) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| SG10201909060SA (en) * | 2014-12-11 | 2019-11-28 | Beta Pharma Inc | Substituted 2-anilinopyrimidine derivatives as egfr modulators |
| CN113563332B (zh) | 2014-12-23 | 2024-12-17 | 达纳－法伯癌症研究所公司 | 作为egfr抑制剂的新的嘧啶和治疗病症的方法 |
| AU2016292450B2 (en) * | 2015-07-16 | 2021-03-25 | Centaurus Biopharma Co., Ltd. | Aniline pyrimidine derivatives and uses thereof |
| CN106117185B (zh) | 2015-08-31 | 2017-11-07 | 广州必贝特医药技术有限公司 | 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用 |
| KR102051609B1 (ko) | 2015-08-31 | 2019-12-03 | 우시 상량 바이오테크놀로지 씨오., 엘티디. | 2-아릴아미노피리딘, 피리미딘 또는 트리아진 유도체 및 그 제조방법과 사용 |
| CN106749193B (zh) * | 2015-11-23 | 2020-11-20 | 南京圣和药业股份有限公司 | 吲唑取代的表皮生长因子受体抑制剂及其应用 |
| CN113912648A (zh) * | 2015-12-02 | 2022-01-11 | 深圳市塔吉瑞生物医药有限公司 | 一种二氨基嘧啶化合物及包含该化合物的组合物 |
| CN108779102B (zh) * | 2015-12-27 | 2020-04-21 | 纽弗姆制药有限公司 | 用于治疗癌症及相关疾病和病况的氘代化合物及其组合物和方法 |
| CN106928150B (zh) * | 2015-12-31 | 2020-07-31 | 恩瑞生物医药科技（上海）有限公司 | 丙烯酰胺苯胺衍生物及其药学上的应用 |
| KR20180105161A (ko) * | 2016-01-07 | 2018-09-27 | 씨에스 파마테크 리미티드 | Egfr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제 |
| CN108610331A (zh) * | 2016-01-22 | 2018-10-02 | 焦玉奇 | 2-(2,4,5-取代苯胺)嘧啶衍生物 |
| CN107043369A (zh) * | 2016-02-06 | 2017-08-15 | 焦玉奇 | 2‑(2,4,5‑取代苯胺)嘧啶衍生物 |
| CN107188888A (zh) * | 2016-03-15 | 2017-09-22 | 罗欣生物科技（上海）有限公司 | 一种制备甲磺酸迈瑞替尼的方法 |
| CN106279160B (zh) * | 2016-03-18 | 2017-09-26 | 海南越康生物医药有限公司 | N‑苯基‑2‑氨基嘧啶类化合物制备方法和用途 |
| CN105884687B (zh) * | 2016-04-14 | 2018-06-22 | 梯尔希（南京）药物研发有限公司 | 一种5-苄基苄达明的制备方法 |
| CN119970741A (zh) * | 2016-05-11 | 2025-05-13 | 贝达医药公司 | 作为用于治疗脑癌之治疗剂的2-苯胺基嘧啶衍生物 |
| US10513509B2 (en) * | 2016-05-26 | 2019-12-24 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
| CN109937043A (zh) * | 2016-06-17 | 2019-06-25 | 贝达医药公司 | N-(2-(2-(二甲基氨基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)氨基)苯基)丙烯酰胺的药物盐及其晶型 |
| CN107540661A (zh) * | 2016-06-24 | 2018-01-05 | 正大天晴药业集团股份有限公司 | 作为egfr抑制剂的苯胺嘧啶化合物的结晶 |
| JP6740452B2 (ja) * | 2016-07-26 | 2020-08-12 | 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． | プロテインチロシンキナーゼの活性を阻害するためのアミノピリミジン系化合物 |
| CN107840846B (zh) * | 2016-09-19 | 2020-11-24 | 郑州泰基鸿诺医药股份有限公司 | 一种含嘧啶环的化合物、egfr抑制剂及其应用 |
| CN118561815A (zh) * | 2016-10-21 | 2024-08-30 | 益方生物科技(上海)股份有限公司 | 一种三氟乙基取代吲哚的苯胺嘧啶化合物及其盐的结晶 |
| CN107973783B (zh) * | 2016-10-21 | 2024-09-06 | 正大天晴药业集团股份有限公司 | 作为erk抑制剂的苯胺嘧啶衍生物 |
| CN108057036B (zh) * | 2016-11-07 | 2023-06-13 | 正大天晴药业集团股份有限公司 | 一种egfr抑制剂的固体药物组合物 |
| CN106957304B (zh) * | 2017-04-25 | 2017-12-01 | 孔令廷 | 一种石墨烯负载FeCl3催化剂的制备方法及其在制备抗癌药物中间体的用途 |
| AU2018286221B2 (en) * | 2017-06-13 | 2021-02-25 | Beijing Adamadle Biotechnology Limited Liability Company | Aminopyrimidine compound, preparation method therefor and use thereof |
| WO2018232235A1 (en) | 2017-06-16 | 2018-12-20 | Beta Pharma, Inc. | Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| CN107266437B (zh) * | 2017-07-19 | 2019-08-30 | 海南越康生物医药有限公司 | N-苯基-2-氨基嘧啶类化合物的晶型、盐型及其制备方法 |
| CN107721991B (zh) * | 2017-11-17 | 2019-10-18 | 南方医科大学中西医结合医院 | 一种6-(嘧啶-4-基)-1h-吲唑衍生物及其制备方法和应用 |
| CN107935995A (zh) * | 2017-11-28 | 2018-04-20 | 中山大学 | 一种新型2‑苯胺基嘧啶衍生物及其在制备抗肿瘤药物中的应用 |
| CN111727272B (zh) | 2017-12-20 | 2023-04-28 | 巴斯夫欧洲公司 | 产生含金属膜的方法 |
| CN108558832B (zh) * | 2018-01-17 | 2021-04-30 | 浙江树人学院 | 一种新型抗肿瘤药物奥希替尼衍生物及其制备方法 |
| CN110272420A (zh) * | 2018-03-16 | 2019-09-24 | 江苏正大丰海制药有限公司 | 氘代3-(4,5-取代氨基嘧啶)苯基化合物单甲磺酸盐晶型及其制备方法 |
| WO2019218987A1 (en) * | 2018-05-15 | 2019-11-21 | Inventisbio Shanghai Ltd. | Egfr inhibitors |
| CN108675993A (zh) * | 2018-06-14 | 2018-10-19 | 纽瑞森生物科技（北京）有限公司 | 氘代嘧啶类化合物、制备方法、药物组合物、制剂和用途 |
| MX2020013808A (es) * | 2018-06-18 | 2021-05-27 | UCB Biopharma SRL | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. |
| CN110698461B (zh) * | 2018-07-09 | 2024-04-05 | 上海翰森生物医药科技有限公司 | 第三代egfr抑制剂的制备方法 |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| US10376512B1 (en) | 2018-08-09 | 2019-08-13 | Chia Tai Tianqing Pharmaeutical Group Co., Ltd. | Crystal of aniline pyrimidine compound of trifluoroethyl substituted indole and salt thereof |
| WO2020119739A1 (zh) * | 2018-12-12 | 2020-06-18 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| CN111410667B (zh) * | 2019-01-08 | 2024-11-22 | 武汉宇科源医药生物科技有限公司 | 新型(1,2,4)三唑并(1,5-a)吡啶基磷氧化物及其用途 |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN111747931A (zh) * | 2019-03-29 | 2020-10-09 | 深圳福沃药业有限公司 | 用于治疗癌症的氮杂芳环酰胺衍生物 |
| CN110016017A (zh) * | 2019-05-16 | 2019-07-16 | 益方生物科技（上海）有限公司 | 一类嘧啶化合物的盐、多晶型物及其药物组合物、制备方法和应用 |
| US20220229072A1 (en) | 2019-06-04 | 2022-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| WO2020256477A1 (ko) * | 2019-06-20 | 2020-12-24 | 주식회사 온코빅스 | 암 세포 성장을 억제하는 피리미딘 유도체 및 이의 의약 용도 |
| CN110229143A (zh) * | 2019-06-21 | 2019-09-13 | 益方生物科技（上海）有限公司 | 一类嘧啶化合物的盐、多晶型物及其药物组合物、制备方法和应用 |
| AU2020308814A1 (en) | 2019-06-27 | 2022-02-03 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents |
| CN114430681A (zh) * | 2019-09-23 | 2022-05-03 | 贝达医药公司 | 使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症 |
| KR20210038366A (ko) * | 2019-09-30 | 2021-04-07 | 한미약품 주식회사 | Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| CN113179640B (zh) * | 2019-11-26 | 2024-06-25 | 上海翰森生物医药科技有限公司 | 含氮多环类衍生物抑制剂、其制备方法和应用 |
| CN110898026A (zh) * | 2019-12-11 | 2020-03-24 | 倍而达药业（苏州）有限公司 | 包含bpi-7711的药用组合物及其制备方法 |
| CN111100117B (zh) * | 2019-12-18 | 2021-02-19 | 上海倍而达药业有限公司 | 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用 |
| CN111057073A (zh) * | 2019-12-26 | 2020-04-24 | 浙江工业大学 | 一种4-吲哚-2-芳胺基嘧啶化合物及其在炎症治疗中的应用 |
| WO2021148396A1 (en) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN113354622B (zh) * | 2020-03-06 | 2022-11-01 | 沈阳药科大学 | 对苯二胺类lsd1抑制剂及其制备方法 |
| CN115175902B (zh) * | 2020-03-13 | 2024-07-26 | 郑州同源康医药有限公司 | 一类用作激酶抑制剂的化合物及其应用 |
| CN113493419A (zh) * | 2020-03-18 | 2021-10-12 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| WO2021243596A1 (en) * | 2020-06-03 | 2021-12-09 | InventisBio Co., Ltd. | Aminopyrimidine compounds, preparation methods and uses thereof |
| AU2021341258A1 (en) * | 2020-09-08 | 2023-04-13 | Betta Pharmaceuticals Co., Ltd. | CD73 inhibitor and application thereof in medicine |
| CN112079728B (zh) * | 2020-09-17 | 2022-08-19 | 苏州昊帆生物股份有限公司 | 氘代n,n,n’-三甲基乙二胺类化合物及其制备方法 |
| CN112174870B (zh) * | 2020-10-12 | 2023-07-21 | 蔡霈 | (r)-1-烷烃酰基-2-取代吡咯烷-2-甲酰胺的制备方法及其药用用途 |
| JP7628729B2 (ja) * | 2020-12-02 | 2025-02-12 | 上海和誉生物医薬科技有限公司 | ２，３－ジヒドロ－１Ｈ－ピロロ［３，２－ｂ］ピリジン誘導体、その製造方法および使用 |
| CN112451527B (zh) * | 2020-12-02 | 2022-08-16 | 北京鞍石生物科技有限责任公司 | 氨基嘧啶类化合物的用途 |
| KR20240027583A (ko) * | 2021-04-30 | 2024-03-04 | 수조우 푸허 바이오파마 컴퍼니 리미티드 | 폐암 치료를 위한 피리미디닐아미노벤젠 |
| WO2022237825A1 (zh) * | 2021-05-13 | 2022-11-17 | 上海和誉生物医药科技有限公司 | 具有egfr抑制活性的氮杂芳基衍生物、其制备方法和应用 |
| CA3225475A1 (en) * | 2021-07-13 | 2023-01-19 | ACEA Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| CN113387935B (zh) * | 2021-07-23 | 2022-06-10 | 苏州雅深智慧科技有限公司 | 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途 |
| CN117729922A (zh) * | 2021-08-02 | 2024-03-19 | 贝达药业股份有限公司 | Egfr抑制剂的药物组合及其应用 |
| CN117440945A (zh) * | 2021-08-06 | 2024-01-23 | 上海和誉生物医药科技有限公司 | 嘧啶或吡啶衍生物及其制备方法和在药学上的应用 |
| CN113773305B (zh) * | 2021-09-16 | 2023-08-11 | 中国人民解放军军事科学院军事医学研究院 | 一种氨基嘧啶衍生物及其作为egfr酪氨酸激酶抑制剂的应用 |
| AU2023246862A1 (en) | 2022-03-31 | 2024-10-31 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
| IL317733A (en) | 2022-06-27 | 2025-02-01 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment |
| WO2024008048A1 (zh) * | 2022-07-04 | 2024-01-11 | 杭州德睿智药科技有限公司 | 新型嘧啶或三嗪取代吡啶并杂环化合物 |
| CN119654152A (zh) | 2022-07-08 | 2025-03-18 | 阿斯利康(瑞典)有限公司 | 与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂 |
| WO2024094064A1 (en) * | 2022-11-02 | 2024-05-10 | Suzhou Puhe Biopharma Co., Ltd | Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis |
| CN115925687B (zh) * | 2022-12-29 | 2024-04-02 | 广东省人民医院 | 靶向egfr的化合物、pet分子探针及其制备方法与应用 |
| CN117623937A (zh) * | 2023-10-20 | 2024-03-01 | 金凯(辽宁)生命科技股份有限公司 | 一种n,n,n'-三甲基乙二胺的制备方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
| SI1848414T1 (sl) | 2005-02-03 | 2011-08-31 | Gen Hospital Corp | Postopek za zdravljenje raka, odpornega na gefitinib |
| JP2010506948A (ja) | 2006-10-20 | 2010-03-04 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｃ−ｋｉｔおよびｐｄｇｆｒ受容体を調節するための組成物および方法 |
| CN101622244A (zh) * | 2006-11-03 | 2010-01-06 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| EP2103620A1 (en) | 2006-12-12 | 2009-09-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| EA200900798A1 (ru) | 2006-12-22 | 2010-10-29 | Новартис Аг | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы |
| EA200900799A1 (ru) | 2006-12-22 | 2009-12-30 | Новартис Аг | Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями |
| US7982036B2 (en) | 2007-10-19 | 2011-07-19 | Avila Therapeutics, Inc. | 4,6-disubstitued pyrimidines useful as kinase inhibitors |
| NZ624345A (en) | 2008-06-27 | 2016-07-29 | Celgene Avilomics Res Inc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US9155422B1 (en) * | 2008-09-24 | 2015-10-13 | Susan M. Wohld | Turkey flipper and method for making and using |
| CN101723936B (zh) * | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| AU2009322346B2 (en) | 2008-12-03 | 2015-07-02 | The Scripps Research Institute | Stem cell cultures |
| US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
| KR20120053052A (ko) | 2009-08-25 | 2012-05-24 | 아브락시스 바이오사이언스, 엘엘씨 | 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법 |
| WO2011140338A1 (en) * | 2010-05-05 | 2011-11-10 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| ES2586588T3 (es) * | 2011-01-26 | 2016-10-17 | Nerviano Medical Sciences S.R.L. | Derivados tricíclicos, procedimiento para su preparación y su uso como inhibidores de quinasa |
| WO2012126181A1 (en) * | 2011-03-24 | 2012-09-27 | Ying Luo | Use of kinase inhibitors in preventing and treating inflammatory disorder |
| KR101884010B1 (ko) * | 2011-05-04 | 2018-07-31 | 어리어드 파마슈티칼스, 인코포레이티드 | Egfr-유도된 암의 세포 증식을 억제하는 화합물 |
| CN102363618A (zh) | 2011-07-04 | 2012-02-29 | 华东理工大学 | 一种表皮生长因子受体的新型抑制剂及其应用 |
| EP3333161B1 (en) * | 2011-07-27 | 2020-02-19 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer |
| AU2012311184A1 (en) * | 2011-09-22 | 2014-03-06 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
| HRP20170226T1 (hr) | 2012-01-17 | 2017-04-07 | Astellas Pharma Inc. | Spoj pirazinkarboksamida |
| CN103360407B (zh) | 2012-04-10 | 2016-06-22 | 上海希迈医药科技有限公司 | 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| CN103374000B (zh) | 2012-04-13 | 2015-11-11 | 中国科学院广州生物医药与健康研究院 | 嘧啶并二氮杂卓类化合物及其药用组合物和应用 |
| CN104520291A (zh) | 2012-06-06 | 2015-04-15 | Irm责任有限公司 | 用于调节egfr活性的化合物和组合物 |
| US10112927B2 (en) * | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| BR112015011456A2 (pt) * | 2012-11-20 | 2017-07-11 | Genentech Inc | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| CN104761544B (zh) | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
| CN104860941B (zh) * | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| CN103804303B (zh) | 2014-03-13 | 2015-04-08 | 山东理工大学 | Egfr小分子抑制剂嘧啶衍生物及其制备方法与用途 |
| CN106687457B (zh) | 2014-05-13 | 2020-01-10 | 阿里亚德医药股份有限公司 | 用于激酶抑制的杂芳基化合物 |
| CN111875585B (zh) | 2014-06-12 | 2023-06-23 | 上海艾力斯医药科技股份有限公司 | 一类激酶抑制剂 |
| CA2949793C (en) * | 2014-06-19 | 2024-02-27 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN105254615B (zh) | 2014-07-11 | 2017-02-22 | 杭州华东医药集团新药研究院有限公司 | 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途 |
| CN105315285B (zh) | 2014-07-25 | 2017-12-08 | 上海海雁医药科技有限公司 | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 |
| CN104140418B (zh) | 2014-08-15 | 2016-08-24 | 常州润诺生物科技有限公司 | 2-(2，4，5-取代苯胺)嘧啶衍生物及其用途 |
| CN106458969A (zh) | 2014-08-25 | 2017-02-22 | 四川海思科制药有限公司 | 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途 |
| CN105461695B (zh) | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | 嘧啶或三嗪衍生物及其制备方法和用途 |
| CN105237515B (zh) | 2014-10-10 | 2018-06-05 | 益方生物科技（上海）有限公司 | 氘代嘧啶类化合物、其制备方法、药物组合物和用途 |
| ES2886887T3 (es) * | 2014-10-11 | 2021-12-21 | Shanghai Hansoh Biomedical Co Ltd | Inhibidor de EGFR y preparación y aplicación del mismo |
| CN111170998B (zh) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| SG10201909060SA (en) | 2014-12-11 | 2019-11-28 | Beta Pharma Inc | Substituted 2-anilinopyrimidine derivatives as egfr modulators |
| CN113563332B (zh) | 2014-12-23 | 2024-12-17 | 达纳－法伯癌症研究所公司 | 作为egfr抑制剂的新的嘧啶和治疗病症的方法 |
| AU2016292450B2 (en) | 2015-07-16 | 2021-03-25 | Centaurus Biopharma Co., Ltd. | Aniline pyrimidine derivatives and uses thereof |
| CN105001208A (zh) | 2015-08-06 | 2015-10-28 | 南京雷科星生物技术有限公司 | 一种表皮生长因子受体egfr抑制剂及其制备方法与用途 |
| CN105153122B (zh) | 2015-08-27 | 2018-07-20 | 上海圣考医药科技有限公司 | [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用 |
| CN107540661A (zh) | 2016-06-24 | 2018-01-05 | 正大天晴药业集团股份有限公司 | 作为egfr抑制剂的苯胺嘧啶化合物的结晶 |
-
2015
- 2015-04-01 CN CN201910180890.1A patent/CN111170998B/zh active Active
- 2015-04-01 CN CN201510152615.0A patent/CN105085489B/zh active Active
- 2015-11-05 JP JP2017542257A patent/JP6637058B2/ja active Active
- 2015-11-05 CA CA2966376A patent/CA2966376C/en active Active
- 2015-11-05 CN CN201910491253.6A patent/CN110054618B/zh active Active
- 2015-11-05 EP EP21166266.3A patent/EP3885344B1/en active Active
- 2015-11-05 CN CN201580060134.5A patent/CN107548391B/zh not_active Expired - Fee Related
- 2015-11-05 CN CN202211200422.4A patent/CN115403565B/zh active Active
- 2015-11-05 WO PCT/CN2015/093815 patent/WO2016070816A1/zh not_active Ceased
- 2015-11-05 KR KR1020177015393A patent/KR102560052B1/ko active Active
- 2015-11-05 EP EP15857419.4A patent/EP3216786B1/en active Active
- 2015-11-05 US US15/524,228 patent/US10179784B2/en active Active
- 2015-11-05 ES ES15857419T patent/ES2881622T3/es active Active
-
2017
- 2017-04-30 IL IL252036A patent/IL252036B/en unknown
-
2018
- 2018-12-05 US US16/210,705 patent/US11203589B2/en active Active
-
2021
- 2021-04-15 US US17/231,581 patent/US20210261543A1/en not_active Abandoned
- 2021-09-05 IL IL286165A patent/IL286165B2/en unknown
- 2021-10-12 US US17/499,230 patent/US11498921B1/en active Active
-
2023
- 2023-11-21 US US18/515,890 patent/US20240208967A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286165B1 (en) | Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof | |
| PL3181560T3 (pl) | Pochodna pirydynoamidopirymidyny, sposób jej otrzymywania i zastosowanie | |
| IL252346A0 (en) | Heteroaryl compounds, their preparation and use | |
| EP3138839A4 (en) | Pyridone or pyrimidone derivative, preparation method therefor and application thereof | |
| EP3268362A4 (en) | Substituted pyridines and uses thereof | |
| EP3126362A4 (en) | Anti-fibrotic pyridinones | |
| EP3102171A4 (en) | Systems, methods, and devices for assisting walking for developmentally-delayed toddlers | |
| EP3097078A4 (en) | Pyridines and pyrimidines and use thereof | |
| EP3115361A4 (en) | Heterocyclic compounds, and preparation method and use thereof | |
| EP3218098A4 (en) | Microreactor systems and methods | |
| IL290114A (en) | Pharmaceutical preparations, their preparation and uses | |
| EP3231802A4 (en) | Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof | |
| ZA201805600B (en) | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | |
| GB201408673D0 (en) | Medicaments,uses and methods | |
| EP3093296A4 (en) | Fuc3s4s substituted oligoglycosaminoglycan and preparation method thereof | |
| HUE048394T2 (hu) | Új triazolopirimidinon vagy triazolopyridinone származékok és ezek felhasználása | |
| IL252397A0 (en) | Pharmaceutical preparations, their preparation and uses | |
| EP3157016A4 (en) | Scintillator, preparing method thereof, and application thereof | |
| PL3229843T3 (pl) | Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji | |
| EP3154547A4 (en) | Pyrimidine compounds and methods using the same | |
| IL252461B (en) | Alpha-asrylaldehyde ester, a method for its preparation and application | |
| EP3235816A4 (en) | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof | |
| EP3130588A4 (en) | Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition | |
| PL3228616T3 (pl) | Pochodne pirydyny | |
| HK1260336A1 (en) | Valbenazine salts and polymorphs thereof |